Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor
Aviceda Therapeutics aims to secure $200 million in financing for their latest project. The Boston-based biotech company is on a mission to raise funds to support their innovative work in the field.
In other news, Nerviano has regained the rights to a PARP1 inhibitor, marking a significant development in the industry. This shift in ownership is a notable move that will impact future projects and collaborations.
Additionally, there are updates from Maat Pharma, Secretome Therapeutics, 35Pharma, Medigene, and Doron Therapeutics to look out for. Each of these companies is making strides in the industry and it’s worth keeping an eye on their progress.
Exciting times lie ahead in the world of biotech and pharmaceuticals, with these recent developments paving the way for future innovations and breakthroughs. Stay tuned for more updates on these and other industry news.
